The emerging role of alemtuzumab in chronic lymphocytic leukemia

Clinical Lymphoma and Myeloma

Volumn 6, Issue 2, 2005, Pages 115-121

  Nabhan, Chadi ^a  

^a ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

Author keywords

CD38; CD52; Cytogenetics; IgVH gene; Monoclonal antibodies; ZAP 70

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTIBIOTIC AGENT; CD38 ANTIGEN; CD52 ANTIGEN; COTRIMOXAZOLE; DIPHENHYDRAMINE; FAMCICLOVIR; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; HYDROCORTISONE; IMATINIB; PARACETAMOL; PETHIDINE; PROTEIN KINASE ZAP 70; PROTEIN P53; RITUXIMAB; STEROID; VALACICLOVIR; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL DEATH; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; CYTOMEGALOVIRUS INFECTION; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; DYSPNEA; FEVER; FLU LIKE SYNDROME; GENE DELETION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; IMMUNOGLOBULIN VARIABLE REGION; INJECTION SITE HYPERSENSITIVITY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; LYMPHOCYTOPENIA; MINIMAL RESIDUAL DISEASE; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PROGNOSIS; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; RIGOR; STEM CELL TRANSPLANTATION; TREATMENT DURATION; TREATMENT OUTCOME; DRUG THERAPY; LYMPHOCYTE; METABOLISM; PATHOLOGY; RECURRENT DISEASE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; DRUG THERAPY; GLYCOPROTEINS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOCYTES; RECURRENCE; TREATMENT OUTCOME;

EID: 33644846619     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2005.n.037     Document Type: Review

References (60)

1. Jemal A, Murray T, Ward A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46:219-234.
3. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343:1750-1757.
4. Nabhan C, Gartenhaus RB, Tallman MS. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk Res 2004; 28:429-442.
5. Perkins JG, Flynn JM, Howard RS, et al. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002; 94:2033-2039.
6. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1:118-129.
7. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004; 103:1202-1210.
8. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352:804-815.
9. Keating MJ. Chronic lymphocytic leukemia. Semin Oncol 1999; 26:107-114.
10. Hallek M, Langenmayer I, Nerl C, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999; 93:1732-1737.
11. Juliusson G, Gahrton G. Chromosome aberrations in B-cell chronic lymphocytic leukemia. Pathogenetic and clinical implications. Cancer Genet Cytogenet 1990; 45:143-160.
12. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990; 323:720-724.
13. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910-1916.
14. el Rouby S, Thomas A, Costin D, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82:3452-3459.
15. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85:1580-1589.
16. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347:452-453.
17. Chang CC, Liu CZ, Cleveland RP. Relative importance of CD38 expression over myeloid-associated markers expression in predicting the clinical course of B-CLL patients. Leuk Lymphoma 2003; 44:977-982.
18. Deaglio S, Capobianco A, Bergui L, et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003; 102:2146-2155.
19. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94:1840-1947.
20. Hsi ED, Kopecky KJ, Appelbaum FR, et al. Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. Br J Haematol 2003; 120:1017-1025.
21. Ghia P, Guida G, Stella S, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003; 101:1262-1269.
22. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94:1848-1854.
23. Hamblin TJ, Orchard JA, Gardiner A, et al. Immunoglobulin V genes and CD38 expression in CLL. Blood 2000; 95:2455-2457.
24. Lin K, Sherrington PD, Dennis M, et al. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia [published erratum in Blood 2002; 100:2291). Blood 2002; 100:1404-1409.
25. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IgVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100:1177-1184.
26. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348:1764-1775.
27. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351:893-901.
28. Rai KR, Chiorazzi N. Determining the clinical course and outcome in chronic lymphocytic leukemia. N Engl J Med 2003; 348:1797-1799.
29. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993; 82:807-812.
30. Salisbury JR, Rapson NT, Codd JD, et al. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol 1994; 47:313-317.
31. Hale G, Xia MQ, Tighe HP, et al. The Campath-1 antigen (CDw52). Tissue Antigens 1990; 35:118-127.
32. Dyer MJ, Hale G, Hayhoe FG, et al. Effects of Campath-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73:1431-1439.
33. Riechmann L, Clark M, Waldmann H, et al. Reshaping human antibodies for therapy. Nature 1988; 332:323-327.
34. Hale G, Dyer MJ, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody Campath-1H. Lancet 1988; 2:1394-1399.
35. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20:3891-3897.
36. Rai K, Coutre S, Rizzeri D, et al. Efficacy and Safety of Alemtuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis. Blood 2001; 98:365a.
37. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99:3554-3561.
38. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of Campath-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15:1567-1574.
39. Osterborg A, Fassas AS, Anagnostopoulos A, et al. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996; 93:151-153.
40. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100:768-773.
41. Rai K, Keating M. Patients with refractory B-CLL and T-PLL treated with alemtuzumab in a compassionate basis, a report on efficacy and safety of CAM-511 trial. Blood 2002; 100(suppl):802a (Abstract #1538).
42. Tang SC, Hewitt K, Reis MD, et al. Immunosuppressive toxicity of Campath1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Leuk Lymphoma 1996; 24:93-101.
43. Nguyen DD, Cao TM, Dugan K, et al. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma 2002; 3:105-110.
44. Keating M, Course S, Rai K, et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004; 4:220-227.
45. Bowen AL, Zomas A, Emmett E, et al. Subcutaneous Campath-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 1997; 96:617-619.
46. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002; 99:2245-2247.
47. Elter T, Brochmann P, Jensen M, et al. Development of a new, four weekly schedule (Flucam) with concomittant application of Campath-1H and fludarabine in patients with relapsed/refractory CLL. Blood 2002; 100(suppl):803a (Abstract #3169).
48. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic: leukemia. Blood 2001; 98:1326-1331.
49. Hainsworth JD. First-line and maintenance treatment with rituximab, for patients with indolent non-Hodgkin's lymphoma. Semin Oncol 2003; 30(1 suppl. 2): 9-15.
50. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19:2153-2164.
51. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic: leukemia. J Clin Oncol 2001; 19:2165-2170.
52. Nabhan C, Rosen ST. Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia. Semin Oncol 2002; 29(1 suppl 2):75-80.
53. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101:3413-3415.
54. Nabhan C, Patton D, Gordon LI, et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 2004; 45:2269-2273.
55. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87:4990-4997.
56. Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98:29-35.
57. Provan D, Bartlett-Pandite L, Zwicky C, et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996; 88:2228-2235.
58. O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003; 98:2657-2663.
59. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23:2971-2979.
60. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103:3278-3281.